Opinion|Videos|July 25, 2024
Later-Line Treatment of Patients with Metastatic NSCLC
The Oncology Brothers and Isabel Preeshagul, DO, MBS, share clinical insights on later-line treatment practices for patients with metastatic non–small cell lung cancer.
Advertisement
Advertisement
Related to this article
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.
The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Early Treatment Support and Real-World Care Gaps
4
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
5